Making a case for GLP1 agonists use for alcohol use disorder (AUD) using Swedish registry data. During an 8-year follow-up, individuals with AUD who were also on treatment with GLP1 agonists (for obesity or T2D) were hospitalized less frequently for AUD-related reasons.